ArticleScientific reports2022
Efficacy of 0.01% low dose atropine and its correlation with various factors in myopia control in the Indian population.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Myopia prevention and control in children: a systematic review and network meta-analysis.Eye (London, England) · 2023Pooled it
- Effectiveness of repeated low-level red light in myopia prevention and myopia control.The British journal of ophthalmology · 2024Trial
- Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study.Eye and vision (London, England) · 2025Article
- Government instituted public health policy for myopia control in schools-the overlooked variable in myopia prevention interventions?Eye (London, England) · 2025Article
- Effectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.Frontiers in pharmacology · 2024Article
- Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression.Scientific reports · 2023Article
- A Longitudinal Study Evaluating the Impact of 0.01% Atropine in High Myopic Children (RAMCOM-II Study).Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the efficacy and safety of low-dose atropine compared to placebo in the Indian population and also to study the impact of various modifiable and non-modifiable factors on myopia progression (MP) and drug efficacy (DE). It was a single-centre prospective placebo-controlled interventional study. 43 participants aged 6-16 years with progressive myopia received 0.01% atropine in the right eyes (treatment) and placebo in the left eyes (control) for 1-year. The main outcome measures were annual MP and axial length elongation (ALE) in treatment and control eyes and their percentage difference between two eyes (drug efficacy). Secondary outcome measures were the occurrence of any adverse events and the correlation of MP, ALE, and DE with various factors. 40 participants (80 eyes) completed the follow-up. After 1-year, MP was 0.25 D (IQR 0.13-0.44) and 0.69 D (IQR 0.50-1.0) (p < 0.001) in treatment and control respectively (63.89% reduction) with respective ALE of 0.14 mm (IQR 0.05-0.35) and 0.32 mm (IQR 0.19-0.46) (p < 0.001) (44.44% reduction). No adverse events were noted. Reduction in MP and ALE was statistically significant in all children irrespective of age-group, baseline MP, family history, screen-time, near and outdoor-time. The strongest determinants of annual MP were age (Treatment: r = - 0.418, p = 0.007; Control: r = - 0.452, p = 0.003) and baseline MP (Treatment: r = 0.64, p = 0.000; Control: r = 0.79, p = 0.000). Screen-time in control eyes was associated with greater ALE (r = 0.620, p = 0.042). DE was higher when outdoor time exceeded 2 h/day (p = 0.035) while the efficacy was lower with prolonged near activities (p = 0.03), baseline fast-progressors (p < 0.05) and history of parental myopia (p < 0.05). 0.01% atropine is effective and safe in retarding MP and ALE in Indian eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.